Phase I CHRYSALIS: Amivantamab, an EGFR-MET Bispecific Antibody, in Advanced NSCLC with MET Exon 14 Skipping Mutations

September 8-14, 2021; Virtual Meeting
Phase I results suggest promising clinical activity with amivantamab in unresectable or metastatic NSCLC driven by a MET exon 14 skipping mutation.
Format: Microsoft PowerPoint (.ppt)
File Size: 239 KB
Released: September 23, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Daiichi Sankyo, Inc.
Janssen Pharmaceutica NV
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Related Content

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in immunotherapy for early-stage NSCLC

Justin F. Gainor, MD
Program Director
Stephen V. Liu, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 10, 2022 Expired: January 9, 2023

Drs Enriqueta Felip and Alexander Spira discuss the emerging role of EGFR exon 20 insertion mutations in the management of advanced NSCLC, from Clinical Care Options (CCO)

Enriqueta Felip, MD Alexander Spira, MD, PhD, FACP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: December 28, 2021 Expired: December 27, 2022

From Clinical Care Options (CCO), experts review key data in genitourinary, gastrointestinal, breast, and lung cancers presented at the ESMO 2021 congress

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: December 15, 2021 Expired: December 14, 2022

In this commentary from Clinical Care Options (CCO), Dr. David Planchard provides an overview of the status of EGFR TKI combination therapy for newly diagnosed EGFR-mutated advanced NSCLC.

David Planchard, MD, PhD Released: December 3, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings